#TradFi交易分享挑战

Johnson & Johnson's core investment value: a globally leading healthcare pillar reshaped through strategic focus

Johnson & Johnson's core investment value is accelerating its transformation from a century-old diversified giant to a high barrier, high cash flow, highly predictable innovative healthcare platform. In fiscal year 2025, its revenue reached $94.2 billion, net profit $26.8 billion, gross margin remained at 68.7%, operating cash flow exceeded $24.5 billion, with financial resilience far surpassing industry averages, making it a rare "counter-cyclical" asset in the global healthcare sector. This performance is built on a precise focus after the complete divestment of its consumer health business (Kenvue)—now Johnson & Johnson is 100% focused on two high-growth engines: innovative pharmaceuticals and medical technology.

On the pharmaceutical side, its three blockbuster drugs—Darzalex (multiple myeloma), Stelara (psoriasis/Crohn’s disease), Carvykti (CAR-T cell therapy)—form the "golden triangle," with total sales surpassing $30 billion in 2025, among which Carvykti’s annual growth exceeds 60%, making it one of the fastest-growing cell therapy products globally. The company continues to invest heavily in immunology, oncology, and neuroscience, with 12 innovative drugs in Phase III clinical trials covering unmet needs such as Alzheimer’s disease and autoimmune disorders. Patent barriers and clinical translation capabilities have built an insurmountable moat.

On the medical technology side, Johnson & Johnson, through the $16.6 billion acquisition of Abiomed, has gained control of the world’s leading ventricular assist device (Impella) and minimally invasive surgical robot platforms, becoming a provider of infrastructure for heart failure treatment and precision surgery. Its electrophysiology, orthopedics, and endoscopic imaging systems are deeply embedded in top hospitals worldwide, with high dependence from doctors and high switching costs, forming dual barriers of "technology lock-in + clinical stickiness." In China, Johnson & Johnson Medical Technology established its first Asia-Pacific digital medical innovation center in Shanghai, collaborating with AI companies to develop intraoperative real-time navigation systems, promoting surgical intelligence, and becoming a bridgehead for its global technological deployment.

Currently, the market still significantly undervalues Johnson & Johnson relative to its growth potential. Morgan Stanley maintains a "Neutral" rating but has raised its target price to $169, reflecting a revaluation of its stable cash flow, pipeline explosiveness, and geopolitical safety redundancy. As a long-term component of the Dow Jones Industrial Average, Johnson & Johnson has 61 consecutive years of dividend growth, with a dividend yield above 2.8%, making it an indispensable low-volatility, high-yield core asset in global institutional "tech + healthcare" portfolios. It no longer relies on consumer brands but redefines the long-term value coordinates of healthcare companies based on science, leveraging technology, and focusing on patient needs.